Vaxx Paves the Way for Life-Changing Innovation: Accelerating Canada's HIV Research with Cutting-Edge Cell & Gene Therapies

An article by Maxime Bilodeau in University Affairs provides a stark reality check on how Canada is lagging behind in HIV research. It cites underfunding and slow adoption of emerging technologies: https://universityaffairs.ca/features/feature-article/canada-is-falling-behind-when-it-comes-to-hiv-research/.

Vaxx Research Incorporated (VAXX) aims to close this gap by leveraging its cell and gene therapy expertise to accelerate HIV research and treatment innovation. By applying cutting-edge technologies such as CRISPR, immune cell engineering, mRNA lipid-based nanoparticles, and adoptive cell therapy, Vaxx's scientists are developing advanced therapies that could provide functional cures, moving beyond the need for lifelong treatments.

Furthermore, Vaxx is actively collaborating with Canadian institutions to establish a dedicated AI-powered research platform for HIV, focusing on novel gene therapies and precision medicine. These advancements aim to restore Canada's leadership in HIV research and pioneer breakthroughs in prevention and potential cures.